keyword
MENU ▼
Read by QxMD icon Read
search

psoriasis, remission

keyword
https://www.readbyqxmd.com/read/28532819/il-23-th17-targeted-therapies-in-sapho-syndrome-a-case-series
#1
Daniel Wendling, François Aubin, Frank Verhoeven, Clément Prati
SAPHO syndrome is a rare entity with skin and rheumatologic inflammatory presentation. The treatment is not standardized, and in case of inadequate response to anti inflammatory drugs, the use of anti TNF or anti IL-1 biologic treatments has been reported. The IL-23/Th17 axis may be involved in SAPHO syndrome. We report the results of six courses of IL-23 and IL-17 targeted therapies (3 ustekinumab and 3 secukinumab) in patients with SAPHO syndrome unresponsive to previous treatments (csDMARDs and bDMARDs)...
May 19, 2017: Joint, Bone, Spine: Revue du Rhumatisme
https://www.readbyqxmd.com/read/28452721/ilven-complete-remission-after-administration-of-topical-corticosteroid-case-review
#2
U Wollina, G Tchernev
Inflammatory linear verrucous epidermal nevus (ILVEN) is a relatively rare disorder with an onset at early age, consisting of pruritic linear papules and/or plaques and histologic features resembling psoriasis or lichenoid dermatitis. The disease is a version of mosaicism caused by somatic mutations. ILVEN belongs to the heterogeneous group of congenital hamartomas of embryonal ectodermal origin, as a variant of verrucous epidermal nevus, representing approximately 5% of all epidermal nevi, with predominance in females and with general therapeutic resistance...
February 2017: Georgian Medical News
https://www.readbyqxmd.com/read/28436109/efficiency-of-ustekinumab-in-crohn-s-disease-with-severe-psoriasiform-rash-induced-by-biotherapies-in-an-adolescent
#3
Valérie Bertrand, Abdelaziz El Haite, Delphine Carré
Ustekinumab is approved for the treatment of psoriasis in adolescents and for the treatment of moderate to severe Crohn's disease (CD) in adults, but data are lacking in pediatric CD. We report a case of severe psoriasis induced by biotherapies in an adolescent with CD that improved after switching to ustekinumab (90 mg at weeks 0, 2, and 4 and then every 8 weeks). The patient had not experienced CD relapse after 1 year of follow-up. Ustekinumab can be an alternative therapy for psoriasis induced by biotherapies when conventional treatment fails and can maintain remission of CD...
April 23, 2017: Pediatric Dermatology
https://www.readbyqxmd.com/read/28408798/an-open-randomized-active-controlled-clinical-trial-with-low-dose-ska-cytokines-versus-dmards-evaluating-low-disease-activity-maintenance-in-patients-with-rheumatoid-arthritis
#4
RANDOMIZED CONTROLLED TRIAL
L S Martin-Martin, F Giovannangeli, E Bizzi, U Massafra, E Ballanti, M Cassol, A Migliore
BACKGROUND: Biologic agents are currently the strongest immunosuppressive drugs able to induce remission in rheumatoid arthritis (RA). One of the objectives of the medical scientific community now is how to maintain remission or low disease activity (LDA). The aim of this trial is to evaluate the contribution of low-dose sequential kinetic activation (SKA) IL-4, IL-10, and anti-IL-1 antibodies (10 fg/mL) in patients affected by RA in maintaining LDA or remission obtained after biological therapy...
2017: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/28369847/palmoplantar-pustulosis-and-pustulotic-arthro-osteitis-treatment-with-potassium-iodide-and-tetracycline-a-novel-remedy-with-an-old-drug-a-review-of-25-patients
#5
Shujiro Hayashi, Yayoi Shimaoka, Yoichiro Hamasaki, Atsushi Hatamochi
BACKGROUND: The use of potassium iodide (KI) to treat palmoplantar pustulosis (PPP) and pustulotic arthro-osteitis (PAO) has not previously been reported. Here, we report the first successful treatment of PPP and PAO with KI. PATIENT AND METHODS: Among 25 patients with PPP, seven had an associated PAO. All patients were administered 900 mg KI three times per day for 3 months. Overall, 12 patients received this medical treatment for the first time or had >6 months interval since the last therapy for PPP...
March 30, 2017: International Journal of Dermatology
https://www.readbyqxmd.com/read/28367894/roles-of-serum-uric-acid-prolactin-levels-and-psychosocial-factors-in-oral-lichen-planus
#6
Akanksha Gupta, Ravi Prakash S Mohan, Swati Gupta, Sangeeta S Malik, Sumit Goel, Nagaraju Kamarthi
Free radicals play important roles in the mechanisms underlying lichen planus (LP). Uric acid (UA) is an important anti-oxidant in plasma. Prolactin (PRL) is an immunomodulatory hormone that may promote LP, as has been documented in other autoimmune disorders, such as systemic lupus erythematosus, rheumatoid arthritis, and psoriasis. PRL has multiple immune-stimulatory effects and promotes the development of such autoimmune disorders. Prolactin and uric acid may serve as biomarkers of disease activity in lichen planus...
2017: Journal of Oral Science
https://www.readbyqxmd.com/read/28249066/global-skin-disease-morbidity-and-mortality-an-update-from-the-global-burden-of-disease-study-2013
#7
Chante Karimkhani, Robert P Dellavalle, Luc E Coffeng, Carsten Flohr, Roderick J Hay, Sinéad M Langan, Elaine O Nsoesie, Alize J Ferrari, Holly E Erskine, Jonathan I Silverberg, Theo Vos, Mohsen Naghavi
Importance: Disability secondary to skin conditions is substantial worldwide. The Global Burden of Disease Study 2013 includes estimates of global morbidity and mortality due to skin diseases. Objective: To measure the burden of skin diseases worldwide. Data Sources: For nonfatal estimates, data were found by literature search using PubMed and Google Scholar in English and Spanish for years 1980 through 2013 and by accessing administrative data on hospital inpatient and outpatient episodes...
May 1, 2017: JAMA Dermatology
https://www.readbyqxmd.com/read/28225955/the-role-of-intradermal-proliferation-of-t-cells-in-the-pathogenesis-of-psoriasis
#8
Vladislav R Khairutdinov, Anastasiya F Mikhailichenko, Irena E Belousova, Ekatherina Sh Kuligina, Alexey V Samtsov, Evgeny N Imyanitov
BACKGROUND: Psoriasis is a common immune-mediated chronic inflammatory disease of the skin and joints, affecting 1-3% of the population. It is generally accepted that the pathogenesis of psoriasis involves accumulation of effector T-cells within lymph nodes and their subsequent migration into the skin through the blood system. Here we provide evidence that psoriatic plaque itself may serve as a source of inflammatory T-cells. OBJECTIVE: We examined the intradermal proliferation of T-cells and the number of effector/memory (CD45RO+) T-cells in the skin of psoriatic patients at different periods of the disease...
January 2017: Anais Brasileiros de Dermatologia
https://www.readbyqxmd.com/read/28222745/psoriasis-and-associated-variables-in-classification-and-outcome-of-juvenile-idiopathic-arthritis-an-eight-year-follow-up-study
#9
Maria Ekelund, Kristiina Aalto, Anders Fasth, Troels Herlin, Susan Nielsen, Ellen Nordal, Suvi Peltoniemi, Marite Rygg, Marek Zak, Lillemor Berntson
BACKGROUND: To study the impact of psoriasis and features associated with psoriasis on classification and outcome in a population-based follow-up cohort of children with juvenile idiopathic arthritis (JIA). METHODS: In all, 440 children with JIA were followed for a median of 8 years in a prospective Nordic population-based cohort study. Data for remission was available for 427 of these children. The presence of psoriasis, psoriasis-like rash, dactylitis, nail pitting, enthesitis, tenosynovitis and heredity was assessed in relation to ILAR classification and remission...
February 22, 2017: Pediatric Rheumatology Online Journal
https://www.readbyqxmd.com/read/28211161/psoriasis-and-psoriasiform-eruptions-in-pediatric-patients-with-inflammatory-bowel-disease-treated-with-anti-tumor-necrosis-factor-alpha-agents
#10
Joshua B Eickstaedt, Luke Killpack, Jeanne Tung, Dawn Davis, Jennifer L Hand, Megha M Tollefson
BACKGROUND: Anti-tumor necrosis factor alpha (TNF-α) agents are used to treat a variety of autoimmune and inflammatory conditions, including psoriasis. Paradoxically, numerous reports have documented new-onset or exacerbation of psoriasis or psoriasiform skin lesions (PSO) in patients treated with these agents for conditions other than PSO-particularly in adults with inflammatory bowel disease (IBD). Not much is known regarding similar cases in children. METHODS: A retrospective chart review was performed on children younger than 19 years of age with IBD seen at the Mayo Clinic between 2003 and 2015 who developed new-onset or recurrent PSO while undergoing anti-TNF-α therapy...
February 17, 2017: Pediatric Dermatology
https://www.readbyqxmd.com/read/28179246/legionella-pneumophila-pneumonia-possibly-due-to-ustekinumab-therapy-in-a-patient-with-crohn-s-disease
#11
Joaquín Borrás-Blasco, Xavier Cortes, Sergio Fernandez-Martinez, Elvira Casterá, Beatriz Antequera
PURPOSE: A case report of Legionella pneumophila pneumonia associated with off-label use of ustekinumab in a patient with Crohn's disease (CD) is presented. SUMMARY: A 57-year-old man with longstanding CD was hospitalized with a four-day history of fever (38.5 °C), dyspnea, left pleuritic pain, and weight loss (more than 6 kg) about six weeks after beginning treatment with ustekinumab, a human monoclonal antibody approved in the United States for two indications (plaque psoriasis and psoriatic arthritis) and currently under investigation as a potential treatment for CD and other inflammatory disorders...
February 15, 2017: American Journal of Health-system Pharmacy: AJHP
https://www.readbyqxmd.com/read/28165883/the-role-of-il-23-in-the-treatment-of-psoriasis
#12
Lluís Puig
The IL-23/IL-17 axis is currently considered to be crucial in the pathogenesis of psoriasis. Human IL-23 is primarily produced by antigen-presenting cells and induces and maintains differentiation of Th17 cells and Th22 cells, a primary cellular source of proinflammatory cytokines such as IL-17 and IL-22, which mediate the epidermal hyperplasia, keratinocyte immune activation and tissue inflammation inherent in psoriasis. Agents that target the p40 subunit common to both IL-12 and IL-23 have shown robust clinical activity, but selectivity for IL-23p19 could offer advantages in efficacy and safety with respect to anti-p40 blockade...
June 2017: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/28148701/need-for-improvement-in-current-treatment-of-psoriatic-arthritis-study-of-an-outpatient-clinic-population
#13
Brigitte Michelsen, Andreas P Diamantopoulos, Hege Kilander Høiberg, Dag Magnar Soldal, Arthur Kavanaugh, Glenn Haugeberg
OBJECTIVE: To explore the burden of skin, joint, and entheses manifestations in a representative psoriatic arthritis (PsA) outpatient cohort in the biologic treatment era. METHODS: This was a cross-sectional study of 141 PsA outpatients fulfilling the ClASsification for Psoriatic ARthritis (CASPAR) criteria and examined between January 2013 and May 2014. Selected disease activity measures were explored including Disease Activity index for PSoriatic Arthritis (DAPSA), Composite Psoriatic Disease Activity Index (CPDAI), Psoriatic Arthritis Disease Activity Score (PASDAS), Disease Activity Score for 28 joints (DAS28), Simplified Disease Activity Index (SDAI), and Psoriasis Area Severity Index (PASI)...
February 1, 2017: Journal of Rheumatology
https://www.readbyqxmd.com/read/28148280/optimizing-adalimumab-treatment-in-psoriasis-with-concomitant-methotrexate-optimap-study-protocol-for-a-pragmatic-single-blinded-investigator-initiated-randomized-controlled-trial
#14
C I Busard, S P Menting, J S van Bezooijen, J M van den Reek, B A Hutten, E P Prens, E M de Jong, M B van Doorn, P I Spuls
BACKGROUND: The introduction of anti-tumor necrosis factor medications has revolutionized the treatment of psoriasis with achievement of treatment goals (Psoriasis Area and Severity Index score 75, remission) that are not usually met with conventional systemics. Nevertheless, some patients continue to experience persistent disease activity or treatment failure over time. Strategies to optimize treatment outcomes include the use of concomitant methotrexate, which has demonstrated beneficial effects on pharmacokinetics and treatment efficacy in psoriasis and other inflammatory diseases...
February 2, 2017: Trials
https://www.readbyqxmd.com/read/28146329/dose-adjustment-of-biologic-therapies-for-psoriasis-in-dermatological-practice-a-retrospective-study
#15
M Esposito, P Gisondi, A Conti, A Giunta, M Del Giglio, M Di Mercurio, L Veneziano, G Ferrucci, L Bianchi, S Chimenti, G Girolomoni
INTRODUCTION: Despite the large routine use of biologic drugs in psoriasis treatment, the majority of studies do not take into consideration dose-adjustment practice in 'real-life' dermatological setting. In routine clinical practice, the disease management may include a large number of conditions requiring non-standard dosage regimens, including dose escalation, dose reduction and/or off-label treatment interruption. OBJECTIVE: The ONDA (Outcome of non-standard dosing regimen in Psoriasis and Psoriatic Arthritis) study aim was to retrospectively analyse dose-adjustment strategies among biologic therapies for psoriasis in dermatological practice during a 3-year period...
February 1, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28134599/new-onset-or-worsening-of-psoriasis-following-biologic-therapy-a-case-series
#16
Vincenzo Bruzzese, Vincenzo De Francesco, Cesare Hassan, Roberto Lorenzetti, Palma Scolieri, Cinzia Marrese, Angelo Zullo
Biologic therapies may cause so-called "paradoxical side-effects," that is, the onset or exacerbation of new symptoms/diseases for which biological treatment should be effective. Among these, psoriatic skin lesions have been described. We report a case series of ten patients with either new onset (seven cases) or worsening (three cases) of psoriasis occurring during a biologic therapy. Six patients were receiving a biologic monotherapy, while four patients were in combination treatment with methotrexate (MTX)...
January 1, 2017: International Journal of Immunopathology and Pharmacology
https://www.readbyqxmd.com/read/28129666/non-invasive-proteome-analysis-of-psoriatic-stratum-corneum-reflects-pathophysiological-pathways-and-is-useful-for-drug-profiling
#17
B Méhul, G Laffet, A Séraïdaris, L Russo, P Fogel, I Carlavan, C Pernin, P Andres, C Queille-Roussel, J J Voegel
BACKGROUND: Protein expression is disturbed in psoriatic stratum corneum. Non-invasive methods for the description of pathophysiological changes and drug profiling in psoriasis are desirable. OBJECTIVES: Undertake large scale non-invasive protein expression studies in psoriatic stratum corneum to identify biomarkers of pathophysiological processes and use them for drug profiling. METHODS: Psoriatic stratum corneum was harvested through repetitive tape-stripping...
January 27, 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/28128277/primary-cutaneous-aggressive-epidermotropic-cytotoxic-t-cell-lymphomas-reappraisal-of-a-provisional-entity-in-the-2016-who-classification-of-cutaneous-lymphomas
#18
Joan Guitart, M Estela Martinez-Escala, Antonio Subtil, Madeleine Duvic, Melissa P Pulitzer, Elise A Olsen, Ellen Kim, Alain H Rook, Sara S Samimi, Gary S Wood, Michael Girardi, Jacqueline Junkins-Hopkins, Doina S Ivan, M Angelica Selim, Kimberly A Sable, Pooja Virmani, Laura B Pincus, Michael T Tetzlaff, Jinah Kim, Youn H Kim
Primary cutaneous CD8-positive aggressive epidermotropic T-cell lymphoma is a rare and poorly characterized variant of cutaneous lymphoma still considered a provisional entity in the latest 2016 World Health Organization Classification of Cutaneous lymphomas. We sought to better characterize and provide diagnostic and therapeutic guidance of this rare cutaneous lymphoma. Thirty-four patients with a median age of 77 years (range 19-89 years) presented primarily with extensive annular necrotic plaques or tumor lesions with frequent mucous membrane involvement...
May 2017: Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc
https://www.readbyqxmd.com/read/28119289/synovial-features-of-patients-with-rheumatoid-arthritis-and-psoriatic-arthritis-in-clinical-and-ultrasound-remission-differ-under-anti-tnf-therapy-a-clue-to-interpret-different-chances-of-relapse-after-clinical-remission
#19
Stefano Alivernini, Barbara Tolusso, Luca Petricca, Laura Bui, Gabriele Di Sante, Giusy Peluso, Roberta Benvenuto, Anna Laura Fedele, Franco Federico, Gianfranco Ferraccioli, Elisa Gremese
OBJECTIVE: To define the synovial characteristics of patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA) in clinical and ultrasound remission achieved by combination therapy with methotrexate (MTX) and tumour necrosis factor (TNF) blockers. METHODS: Patients with RA in remission (n=25) (disease activity score (DAS)<1.6 for at least 6 months), patients with RA in low disease activity (LDA) (n=10) (1.6<DAS<2.4 for at least 6 months) and patients with PsA in remission (n=18) (DAS<1...
January 24, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28074414/spontaneous-remission-of-subcutaneous-scedosporiosis-caused-by-scedosporium-dehoogii-in-a-psoriatic-patient
#20
Fang-Gu Li, Yan-Ping Yang, Wei Li, Ping Sheng, Wen Li, Wen-Ming Huang, Yi-Ming Fan
To date, only one case of post-traumatic endophthalmitis caused by Scedosporium dehoogii has been reported, but its contamination or colonization might not be precluded due to the absence of pathogenic isolation and/or pathological examination. We report the first case to our knowledge of S. dehoogii-induced subcutaneous scedosporiosis in a psoriatic patient. A 58-year-old man with 5-year history of psoriasis vulgaris and immunosuppressant therapy developed pyrexia and multiple subcutaneous abscesses on both knees...
June 2017: Mycopathologia
keyword
keyword
108076
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"